Knowles Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 16% revenue growth and 50% EPS growth year-over-year, with strong performance in both MedTech & Specialty Audio and Precision Devices segments. Guidance for Q2 and full-year 2026 points to continued revenue and margin expansion, driven by robust demand and successful capacity investments.
Fiscal Year 2025
-
Revenue and EPS exceeded guidance for both Q4 and full year, driven by strong growth in Precision Devices and MedTech & Specialty Audio. Robust bookings, a healthy backlog, and major capacity expansions position the company for continued growth and margin improvement into 2026.
-
The company has completed a strategic transformation, focusing on high-margin medtech, defense, and industrial markets. With strong cash flow, disciplined M&A, and a robust growth outlook, it targets 8%-10% annual revenue growth and 30% EBITDA margins within five years.
-
Q3 2025 saw 7% revenue and 22% EPS growth, with strong cash flow and robust segment performance. Guidance calls for continued revenue and margin expansion, driven by specialty film and defense, while capital allocation remains disciplined and the balance sheet strong.
-
A major transformation shifted focus to high-margin MedTech, defense, and industrial markets, with divestitures and acquisitions strengthening the portfolio. Financial performance has improved, with strong growth and margin expansion projected. Differentiated technology, customer intimacy, and disciplined capital allocation underpin future growth.
-
Q2 2025 saw 8% revenue growth and 20% EPS growth year-over-year, with both segments outperforming and strong cash flow enabling $30 million in share buybacks. Guidance points to continued sequential and year-over-year growth, supported by robust bookings and new product initiatives.
-
Completed a strategic transformation to focus on high-growth, high-margin industrial tech markets, targeting 8–10% annual revenue growth and 10–14% EBITDA growth over the next five years. Growth will be driven by organic initiatives, new product launches in specialty film capacitors and inductors, and disciplined M&A, with robust cash flow supporting continued investment and shareholder returns.
-
Announced the EUR 550 million SIKORA acquisition, enhancing the polymer processing platform and cross-selling opportunities. Biopharma, CO2 systems, and clean energy segments are driving double-digit growth, while automation and supply chain flexibility support operational resilience.
-
Q1 2025 revenue was $132M with EPS of $0.18, both at or above guidance, and strong cash flow. Minimal tariff exposure, robust bookings, and normalized inventories support confidence in year-over-year growth, with Q2 revenue expected at $135–$145M.
Fiscal Year 2024
-
Q4 2024 revenue and EPS were within guidance, with full-year growth driven by MedTech, Specialty Audio, and expanded capacitors. A $75M+ specialty film order and strong bookings support 2025–2026 growth, while inventory and tariff risks are being managed.
-
A major portfolio transformation has shifted focus to high-margin MedTech, defense, and industrial markets, with divestitures and acquisitions driving improved margins and growth. The company targets high single-digit revenue CAGR and 15% EPS growth, supported by strong cash flow and disciplined capital allocation.
-
Q3 revenue grew 32% year-over-year to $143 million, driven by the Cornell acquisition and organic growth, with adjusted EBITDA margin at 24.6%. The company signed an agreement to sell its Consumer MEMS Microphones business and expects continued margin expansion and modest sequential growth in Q4.
-
Q2 2024 saw 18% revenue growth to $205M, driven by MedTech, Precision Devices (Cornell acquisition), and CMM. Gross margins improved in MedTech, while Precision Devices and CMM faced margin pressures. Q3 guidance projects continued growth, with strong cash flow supporting share buybacks and debt reduction.